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Abstract
Purpose The use of opioids in patients with chronic non-cancer pain is common and can be associated with opioid-induced 
androgen deficiency (OPIAD) in men. This review aims to evaluate the current literature regarding the prevalence, clinical 
consequence and management of OPIAD.
Methods A database search was performed in Medline, Embase and Cochrane using terms such as “analgesics”, “opioids” 
and “testosterone”. Relevant literature from January 1969 to March 2018 was evaluated.
Results The prevalence of patients with OPIAD ranges from 19 to 86%, depending on the criteria for diagnosis of hypog-
onadism. The opioid-induced suppression of gonadotropin-releasing and luteinizing hormones represents the main important 
pathogenetic mechanisms. OPIAD has significant negative clinical consequences on sexual function, mood, bone density 
and body composition. In addition, OPIAD can also impair pain control leading to hyperalgesia, which can contribute to 
sexual dysfunction and mood impairment.
Conclusions OPIAD is a common adverse effect of opioid treatment and contributes to sexual dysfunction, impairs pain 
relief and reduces overall quality of life. The evaluation of serum testosterone levels should be considered in male chronic 
opioid users and the decision to initiate testosterone treatment should be based on the clinical profile of individuals, in con-
sultation with the patient.
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Introduction
Chronic non-cancer pain (CNCP) is common worldwide, 
with an estimated prevalence of 8–60% [1, 2], and pro-
foundly impacts the overall quality of life and mental health 
of affected individuals [1, 2]. CNCP is a significant eco-
nomic burden for patients, health services and societies, 
costing an estimated $500 billion per annum in the USA, due 
to the impact on absenteeism and worker productivity [3]. 
Moreover, the burden of CNCP is expected to increase as a 
consequence of an aging population and increasing levels of 
obesity, due to lack of physical activity and urbanization [3].
Opioids are an integral part of the World Health Organi-
zation (WHO) analgesic ladder for cancer pain. In the last 
decade, opioids have also been widely used for CNCP; how-
ever, the epidemic of opioid overdose, recently recorded in 
the USA, has led to concerns about their safety [4]. Weak 
opioids or low doses of strong opioids may be safer than 
non-steroidal anti-inflammatory drugs (NSAIDs), particu-
larly in the elderly population, as opioids do not impair 
organ function [5]. However, the effectiveness of opioids 
for long-term use in CNCP has not been established and the 
risk of opioid-related abuse or overdose should be avoided. 
Accordingly, recent guidelines from the US Centers for 
Disease Control and Prevention (CDC) recognize that non-
opioid therapy is preferred for the treatment of CNCP [6]. 
Opioids should be used only when the benefits for pain and 
function outweigh risks [6]; this is supported by other evi-
dence in the literature [7–9].
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Adverse events (AEs) are common in patients treated 
with opioids and usually begin soon after the initiation of 
treatment. The most common AEs occur in the gastroin-
testinal tract and central nervous system (CNS), but new 
concerns are emerging about potential effects on bone and 
joint physiology [10]. Although patients develop tolerance 
for nausea, vomiting and CNS AEs, this is not the case 
for bowel dysfunction, which can persist during the entire 
course of treatment [11, 12].
The endocrine system can also be severely affected by 
chronic opioid treatment. Opioids can influence the secretion 
of hormones at different levels of the hypothalamus–pitui-
tary–gonadal (HPG) axis [13]. Opioids generally increase 
the levels of growth hormone, thyroid-stimulating hormone 
and prolactin, but there are conflicting reports on the effects 
of opioids on arginine vasopressin and adrenocorticotropic 
hormone [13]. In addition, opioids can lead to the develop-
ment of hypogonadism by directly inhibiting gonadotropin-
releasing hormone (GnRH) through the µ-opioid (MOP) 
receptor (Fig. 1), reducing libido and causing erectile dys-
function (ED) in men, oligomenorrhea or amenorrhea in 
women, and bone loss or infertility in both sexes [13]. The 
clinical significance of opioid-induced androgen deficiency 
(OPIAD) and the contribution of testosterone treatment 
(TTh) to improve symptoms of OPIAD has not been com-
pletely clarified [14–18]. Furthermore, the role of TTh in 
medical conditions other than classical hypogonadism has 
been recently the subject of discussion [19]. The aim of this 
review is to evaluate the data on the prevalence of OPIAD 
and the risk/benefit ratio of TTh in this condition.
Methods
A comprehensive Medline, Embase and Cochrane search 
was performed including the following words: (“analge-
sics, opioid”[Pharmacological Action] OR “analgesics, 
opioid”[MeSH Terms] OR (“analgesics”[All Fields] AND 
“opioid”[All Fields]) OR “opioid analgesics”[All Fields] OR 
“opioid”[All Fields]) AND (“testosterone”[MeSH Terms] 
OR “testosterone”[All Fields]).
Publications from January 1, 1969 up to March 30, 2018 
were included.
Opioids and their use in CNCP
Opioids exert their analgesic effects in humans via agonist, 
partial agonist or antagonist activity on opioid receptors, δ 
(DOP), κ (KOP) and μ (MOP) [20]. The classical G-protein-
coupled opioid receptors, known as DOP, KOP and MOP 
[20], are widely distributed in the CNS and to a lesser extent 
in the periphery [21]. Various endogenous ligands derived 
from pro-hormone precursors act at the receptors. Proen-
kephalin binds to DOP receptors and is cleaved to form met-
enkephalin and leu-enkephalin [22]. Dynorphin A and B, 
derived from prodynorphin, are agonists at the KOP receptor 
[23]. Proopiomelanocortin is the precursor of β–endorphin, 
which has agonist activity in all three opioid receptors, but 
principally the MOP receptor [24]. The nociceptin (NOP) 
receptor is a ‘non-classical’ G-protein-coupled receptor; its 
endogenous agonist is derived from a precursor compound, 
Fig. 1  Summary of mechanisms 
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pre-pronociceptin. The NOP receptor is insensitive to the 
prototypical opioid agonist morphine and antagonist nalox-
one (Table 1).
Opioids have been widely used for CNCP, with specific 
recommendations about patient selection, treatment tailor-
ing, dose titration, maintenance therapy, and tapering doses 
during discontinuation [25]. Despite some critical points, 
one in five US patients with CNCP receive prescription opi-
oids [26]. In particular, their endocrine effects can be mini-
mized by using drugs with a lower MOP affinity.
Opioids for CNCP are commonly classified, according to 
their analgesic potency, as weak (codeine and tramadol) for 
mild-to-moderate chronic pain, or strong opioids (morphine, 
oxycodone, fentanyl, hydromorphone, methadone, buprenor-
phine, tapentadol) for severe chronic pain. They may be also 
classified according to their duration of action: long-acting 
opioids (LAO), used to maintain a stable plasma dose during 
chronic therapy, short-acting opioids (SAO), mainly used for 
titration at the beginning of opioid therapy, and rapid-onset 
opioids (ROO) indicated for breakthrough cancer pain.
Codeine is a pro-drug that requires metabolic conversion 
to morphine for analgesic activity. A small proportion of 
the population (5–10%) lacks the enzymes for this meta-
bolic activation and as such are unable to derive pain relief 
from codeine (poor metabolizers) [27]. It is available in fixed 
combination with paracetamol (acetaminophen) for mild-to-
moderate pain [28].
Tramadol is a synthetic piperidine analog of morphine. 
It acts as a central analgesic via MOP receptors and by 
modulating monoaminergic (serotonin and noradrenaline) 
pathways. Because its activity on the MOP receptor is signif-
icantly lower than that of morphine [29], tramadol has less 
potential for respiratory depression and gastrointestinal side 
effects [30, 31]. Tramadol is available in different formula-
tions as SAO, LAO, and in association with paracetamol for 
mild-to-moderate chronic pain [32, 33].
Another weak opioid is meperidine. This agent has 
approximately 10% of the efficacy of morphine and a half-
life of only 3 h after oral administration [34]. It is rapidly 
metabolized to normeperidine, which has a half-life of 
8–12 h and is associated with significant CNS AEs [34].
The strong opioid morphine has been the mainstay of 
chronic pain management. Morphine acts as a full agonist 
of the MOP receptor, with weak agonist activity at DOP and 
KOP receptors (Table 1) [35]. It is commonly administered 
via the oral, intravenous, or intrathecal routes, but morphine 
has low lipid solubility, resulting in slow penetration through 
the blood–brain barrier [36]. Therefore, the onset of the 
analgesic effect is relatively slow and the relative hydro-
philicity impairs its administration through the skin. Oral 
bioavailability is about 30%, because morphine undergoes 
extensive hepatic first-pass metabolism, via glucuronidation 
[37]. Morphine has been shown to significantly decrease 
testosterone plasma levels, probably due to the action on 
opioid receptors present in the testis [17].
Oxycodone is a semi-synthetic derivative of thebaine with 
high oral bioavailability [38]. The extended-release formu-
lations provide stable plasma levels throughout the dosing 
interval and allow twice-daily administration [39]. The fixed 
combination of oxycodone–naloxone 2:1 has significantly 
Table 1  Opioid receptors with 
their endogenous ligands, 
precursors and clinical drugs 
with agonist or antagonist 
activity
− No affinity; + low affinity; ++ intermediate affinity, +++ high affinity
N/OFQ nociception orphanin FQ, DOP delta opioid receptor, KOP kappa opioid receptor, MOP mu opioid 
receptor, NOP nociceptin opioid receptor
Receptor subtype
DOP (δ) KOP (κ) MOP (μ) NOP
Precursor Proenkephalin Prodynorphin Proopiomelancortin Pre-pronociceptin
Peptide Met-enkephalin, 
leu-enkephalin
Dynorphin A, 
dynorphin B
β–endorphin N/OFQ
Agonists
 Morphine + + +++ −
 Fentanyl − + +++ −
 Codeine ++ ++ ++ −
 Oxycodone − +++ +++ −
 Buprenorphine − + ++ +
 Tramadol − − + −
 Methadone + − ++ −
 Meperidine + + ++ −
 Tapentadol − + + −
Antagonist
 Naloxone ++ ++ +++ −
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improved the gastrointestinal tolerability of oxycodone, 
reducing the incidence of opioid-induced bowel dysfunc-
tion [40]. However, when administered in males, oxycodone 
significantly reduces testosterone levels; in one study, 45.5% 
of patients treated with oxycodone (mean 75 mg/day) had 
testosterone values below the normal reference range after 
12 weeks of treatment [41].
Hydromorphone is available for chronic pain manage-
ment as a once-daily formulation, using an osmotic-con-
trolled-release oral delivery system  (OROS®). This formula-
tion is minimally affected by food or alcohol, provides stable 
plasma concentrations and enhances patient adherence to 
treatment by reducing dosing frequency [42].
Fentanyl is a synthetic opioid analgesic with high lipid 
solubility and a faster onset of action than morphine [43]. 
All ROOs are fentanyl based, but their use is not indicated 
for CNCP. In chronic pain management, fentanyl is mainly 
used in transdermal formulations. Compared with oral opi-
oids, transdermal fentanyl is associated with a lower inci-
dence of side effects (constipation, nausea and vomiting, and 
daytime drowsiness), increased patient satisfaction and qual-
ity of life, and improved compliance resulting from admin-
istration every 72 h [44]. However, the convenience of the 
fentanyl patch should be weighed against the highest risk of 
androgen deficiency, when compared with other commonly 
prescribed opioids [45].
The “atypical opioid” tapentadol has a pharmacological 
profile that is distinct from all other opioids. It has a dual 
mechanism of action: µ-opioid receptor agonist/noradrena-
line reuptake inhibitor (MOR/NRI). The affinity of tapen-
tadol for the MOP receptor is 50 times lower than that of 
morphine, which, when counterbalanced by its activity on 
noradrenaline modulation, results in an improved tolerability 
profile, lower rate of tolerance development, lower abuse 
potential, and efficacy in both nociceptive and neuropathic 
pain [46, 47]. Tapentadol has been mainly studied in CNCP, 
including low back pain (LBP), neck pain, osteoarthritis, and 
painful diabetic peripheral neuropathy [48–50]. Compared 
with oxycodone/naloxone, tapentadol at the mean dosage of 
about 378 mg/day had minimal or no significant effects on 
testosterone levels in male patients with severe chronic LBP 
[41], probably related to the dual mechanism of action [51].
Buprenorphine also differs from traditional opioids (pure 
MOP agonists), because it works as a non-selective partial 
opioid agonist. It produces analgesic effects via MOP recep-
tors and also antagonizes morphine antinociception at high 
doses via interaction with the KOP and NOP receptors [52]. 
Furthermore, compared with pure MOP agonists, buprenor-
phine has reduced potential for respiratory depression, over-
dose, and abuse, making it a useful drug for patients with 
chronic pain. At low dosages, transdermal buprenorphine is 
an accepted around-the-clock pain reliever for mild-to-mod-
erate chronic pain [53]. Unlike morphine, buprenorphine has 
only limited endocrine effects and can be used for months 
without inducing hypogonadism [17].
Methadone is a synthetically derived opioid with agonist 
affinity for both the MOP and DOP receptors. Methadone 
has improved safety and tolerability compared with mor-
phine because of its lower affinity for the MOP receptor. 
Methadone is mainly used in patients with chronic cancer 
pain who have reached a high opioid dose or in patients 
with a history of substance abuse as part of a methadone 
maintenance program (MMT) [54]. In these patients using 
high-dose MMT, low serum testosterone levels have been 
reported: the percentage of hypogonadism in men reached 
75%, while in women was only 21% [55].
Opioid‑induced androgen deficiency
Prevalence
The association between reduced testosterone levels, andro-
gen deficiency and opioid treatment has been documented 
since the 1970s, when reports emerged in men who were on 
maintenance methadone therapy [56, 57]. Since then, several 
studies with a limited number of patients have also suggested 
an association between testosterone suppression and opi-
oid treatment [16–18]. A meta-analysis performed in 2015, 
including 17 studies and 800 opioid users and 1969 controls, 
concluded that mean testosterone levels were significantly 
lower in men treated with opioids compared with controls 
[58]. However, the analysis included a heterogeneous group 
of studies in men treated with opioids for different reasons. 
This represents an important limitation because comorbidi-
ties can profoundly influence testosterone levels. Addic-
tive disorders, such as alcohol or opioid dependence, are 
frequently associated with human immunodeficiency virus 
(HIV) and chronic hepatitis, which can affect testosterone 
metabolism through direct (hepatic impairment) and indirect 
(use of retroviral drugs) mechanisms [59–61].
Studies evaluating the impact of opioid treatment on 
testosterone levels in men with CNCP show that the preva-
lence of OPIAD ranges from 19 to 86%, depending on 
the testosterone threshold used to define hypogonadism 
(Table 2) [45, 55, 62–72]. While OPIAD definitions vary, 
most studies report an overall prevalence higher than 50%, 
confirming the significant impact of opioids in reducing 
testosterone levels. Although few studies have investigated 
the impact of opioid dosage or specific drug characteristics 
on testosterone levels, the available evidence suggests an 
increased risk of androgen deficiency with higher opioid 
doses and with SAO than LAO formulations. However, 
in equivalent doses, LAOs are significantly more likely 
than SAOs to cause androgen deficiency in men [69]. 
Doses exceeding approximately 100 mg of oral morphine 
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equivalent may be more likely to trigger the onset of 
OPIAD, compared with lower opioid doses [73], although 
this finding has not been confirmed by other researchers 
[56, 65]. In a more recent study comparing different opioid 
formulations, neither the chemical structure nor the lipo-
philicity of the opioid explained the androgen suppression 
[45]. Certain opioids are associated with an increased risk 
of androgen deficiency. In particular, the risk of androgen 
deficiency is highest with fentanyl, followed by metha-
done and oxycodone [45]. Tapentadol, which has a 50-fold 
lower affinity for the human MOP receptor than morphine, 
has a lower impact on sex hormone concentrations, com-
pared with pure opioid analgesics, supporting the role 
of MOP receptors in the pathogenesis of OPIAD [41, 
74]. In randomized, comparative studies, morphine and 
controlled-release oxycodone reduced serum testosterone 
levels to a greater extent than extended-release tapentadol 
[41, 74]. The presence of comorbidities, particularly dia-
betes, hypertension and dyslipidemia, further increases the 
risk of OPIAD [45]. This is not surprising as several stud-
ies have documented the influence of metabolic diseases 
on different levels of the hypothalamus–pituitary–testis 
axis and testosterone production [75–78].
Pathophysiology
Animal studies The primary mechanism by which opioids 
affect testosterone production is by inhibiting the secretion 
of GnRH (Fig. 1) [12]. Injections of β-endorphin in the ven-
tromedial, anterior and preoptic-septal hypothalamic areas 
decrease the secretion of luteinizing hormone (LH) from the 
pituitary [79]. Li and Pelletier [80] used in situ hybridiza-
tion to demonstrate that morphine down-regulates GnRH 
mRNA levels. Accordingly, chronic morphine administra-
tion inhibits GnRH secretion [13]. However, follicle-stimu-
lating hormone (FSH) levels are not affected by opioid ana-
logs or antagonists [13]. Animal models have also shown 
that opioids can modulate the negative feedback of sex ster-
oids on LH secretion [13]. In male rats, morphine enhances 
the sensitivity of the hypothalamus to negative feedback by 
testosterone [81]. Lastly, there is a possibility that opioids 
can also influence peripheral testosterone metabolism. In a 
rat model, morphine administration increased the expres-
sion of 5-α reductase type 1 and/or P450-aromatase mRNA 
in different body regions (Fig. 1) [82].
Human studies The available data on the OPIAD mecha-
nism in humans reflects the findings of animal models 
Table 2  Summary of the literature evaluating the impact of opioid treatment on testosterone levels in men with non-cancer pain
MSE morphine sulfate equivalent, NR not reported
Publication Study design N Age (years) Type of opioid/
route of adminis-
tration
MSE (mg) Mean testoster-
one level during 
opioids (nmol/L)
Testosterone 
threshold 
for defining 
hypogonadism 
(nmol/L)
Proportion with 
hypogonadism 
(%)
Abs et al. [62] Cohort 29 48.4 Morphine/
intrathecal
4.8 6.8 9.0 86.2
Finch et al. [63] Cross-sectional 11 46.5 Morphine/
intrathecal
0.5–40 4.8 10.0 100
Daniell et al. [64] Cross-sectional 23 49.4 Mixed/oral 70–120 6.5 NR 74.0
Roberts et al. 
[65]
Cohort 10 52.4 Mixed/oral or 
intrathecal
3.3 3.9 10.0 100
Rajagopal et al. 
[66]
Cross-sectional 20 50.1 Mixed/oral > 200 3.9 8.3 90
Fraser et al. [55] Cross-sectional 12 45.4 Mixed/oral or 
transdermal
718 6.9 Age specific 
range
83
Duarte et al. [67] Cross-sectional 20 58.0 Morphine/
intrathecal
2.68 4.9 8 85
Rubinstein et al. 
[68]
Cross-sectional 81 26–79 Mixed/oral 184 NR 8.6 53
Kim et al. [72] Cross-sectional 8 60.1 Intrathecal 12.3 9.1 NR 50
Rubinstein et al. 
[69]
Cross-sectional 1585 54.0 Mixed/oral 76 NR 8.6 43.6
Cepeda et al. [71] Cross-sectional 146 49.1 Mixed/oral NR 11.8 10 35.1
Ajo et al. [70] Cross-sectional 120 58.4 Mixed/oral 77 NR 10 19
Rubinstein et al. 
[45]
Cross-sectional 1159 53.1 Mixed/oral 44 9.9 8.6 38.9
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(Fig. 1) [13]. In healthy, adult men, morphine decreases LH 
pulse frequency, but does not affect FSH levels [13]. It was 
suggested that treatment with opioids impairs gonadotropin 
pulse amplitude or affects the response of the anterior pitui-
tary to GnRH, leading to a decrease in testosterone levels 
[83]. Interestingly, the effect of opioids on the human hypo-
thalamus–pituitary–testis axis differs according to pubertal 
stage [13]. For example, naloxone administration failed to 
increase LH levels in early puberty, whereas it had a stim-
ulatory effect in late pubertal boys [84], suggesting that 
regulation of central opioid receptors by sex hormones is 
dependent on sexual maturity [13]. In addition, opioid tone 
at the hypothalamic–pituitary level seems to change in an 
age-dependent manner. Indeed, in healthy elderly men, opi-
oid tone was lower than in young men, as demonstrated by 
a reduction in the LH pulse amplitude and the frequency of 
high-amplitude pulses after naltrexone administration [85].
Clinical consequences
Opioids can induce several hypogonadism-related signs 
and symptoms, including sexual dysfunction, mood impair-
ment, fatigue, weight gain and osteoporosis [16–18, 86], 
and these are described in more detail in the following sec-
tions. Regardless of the origin of hypogonadism, signs and 
symptoms are dependent on the age at onset [87, 88]. In 
adults and aging men, sexual dysfunction is the most spe-
cific symptom associated with low testosterone [89–91]. 
The European Male Aging Study, a population-based sur-
vey of more than 3400 men across eight European centers, 
showed that low libido, reduced spontaneity and sex-related 
ED were specifically associated with decreased testosterone 
levels, whereas other hypogonadal symptoms (e.g., physical 
and psychological changes) were less specific [89]. Similar 
results have been more recently reported in a population of 
men consulting for sexual dysfunction [100]. Furthermore, 
a large body of evidence has demonstrated that, although 
sexual dysfunction is the most specific symptom of adult-
onset hypogonadism, central obesity may be both a cause 
and effect of hypogonadism [92, 93].
As well as opioids affecting testosterone levels, testoster-
one may also be involved in the regulation of endogenous 
opioid activity. In fact, androgen receptors are involved in 
the transcriptional regulation of the MOP receptor [94]. 
Therefore, in men treated with opioids, hypogonadism may 
manifest as poor control of pain and hyperalgesia, which 
can in turn cause sexual dysfunction and mood impairment.
Sexual function Testosterone regulates male sexual function 
at both a central and peripheral level [95], so the association 
between sexual dysfunction and OPIAD is not surprising. 
However, it is important to recognize that chronic pain can 
also negatively affect sexual function through its associated 
disabilities, physical limitations and psychological distress 
[96, 97]. In addition, opioids can modulate sexual behavior 
by acting on the hypothalamic nuclei in the medial preop-
tic area and the spinal cord [13]. Further evidence support-
ing the negative impact of the endogenous opioid system 
on sexual function is derived from data obtained in patients 
with non-organic ED. Jannini and his group, in Italy, pro-
duced compelling evidence that robustly substantiated the 
hypothesis of an LH-mediated, sex-induced, drive in tes-
tosterone production [98–100] They essentially found that 
restoring sexual activity in patients affected by ED led to 
recovery of an otherwise borderline low testosterone level. 
The testosterone level rise was independent of the type of 
ED therapy employed, but was closely related to the suc-
cessful outcome of therapeutic intervention. Hence, they 
speculated that sexual inertia resets the reproductive axis 
to a lower level of activity, somehow inducing a second-
ary hypogonadism, characterized by reduced LH bioactivity 
[100]. Consequently, restoring sex restores sex hormones, 
including bioavailable LH and testosterone [98–100]. The 
increased tone of the endogenous opioid system is the 
working hypothesis used by these researchers to explain 
their findings [101, 102]. Accordingly, the same research-
ers reported that the administration of naltrexone therapy 
for 7–15 days significantly increased the rate of successful 
coitus compared with placebo in these men [103].
Despite this evidence, few studies using standardized 
methods have evaluated the presence of sexual dysfunction 
in men receiving long-term opioids. In addition, most studies 
evaluating the effect of opioids on sexual function have been 
conducted in people with addictive disorders, limiting the 
generalizability of their findings [13]. A large cross-sectional 
study in 11,327 men with back pain found that the long-term 
use of opioids was associated with increased use of phos-
phodiesterase type 5 inhibitors or TTh [104]. In addition, 
patients prescribed a daily opioid dosage of at least 120 mg 
morphine equivalents reported higher use of medication 
for ED compared with those receiving lower opioid doses 
[104]. A study of 120 men with CNCP, who had been receiv-
ing opioids for at least 12 months, found that 78% reported 
sexual dysfunction according to the International Index of 
Erectile Function (IIEF) score [70]. In most of these patients 
(69%), the sexual dysfunction was severe [96]. In this study, 
19% of patients had OPIAD, defined as a total testoster-
one level < 10.4 nmol/L, and IIEF scores were significantly 
lower in those with OPIAD than in eugonadal men [70]. 
IIEF scores were worse in patients receiving oxycodone than 
other opioids [70], consistent with its more marked effect 
in reducing testosterone levels [45]. In other comparative 
studies of OPIAD and sexual dysfunction, buprenorphine (a 
partial μ-opioid agonist used for opioid dependence) caused 
less marked reduction of testosterone levels and a lower 
incidence of sexual dysfunction, compared with methadone 
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[105]. Standards have not been established for monitoring 
and treating OPIAD patients. However, according to the lit-
erature and expert opinion, patients who use opioids at doses 
higher than 100 mg of morphine equivalents per day should 
be monitored for the development of hypogonadism [86].
Mood The association between CNCP, depression and 
reduced quality of life is well documented [106]. In a large 
national sample of patients prescribed opioids for CNCP 
in Australia (n = 1418), 61% had ever experienced depres-
sion, and 66% of those patients reported depressive symp-
toms in the previous 12 months [107]. Among those who 
had reported lifetime depression, 48% developed depression 
after the onset of pain and the initiation of opioid medica-
tions. Several reports have also documented a dose- and 
duration-dependent association between chronic opioid 
treatment and new-onset depression [106]. One possible 
reason for this association is a reduction in testosterone lev-
els caused by opioid administration [108, 109], with OPIAD 
contributing to the development of depression in patients 
with CNCP. However, the relationship between low tes-
tosterone levels and the incidence of clinical depression is 
still unclear, as is the potential benefit of TTh in men with 
depression or OPIAD [109].
Bone Osteopenia and osteoporosis are well-known conse-
quences of male hypogonadism [110]. Osteopenia has been 
reported in 50% of men treated with opioids for CNCP [55], 
and epidemiological studies have shown that opioid treat-
ment is associated with a 50–60% increase in the risk of 
osteoporotic fractures [86, 111]. Patients older than 60 years, 
who use opioids equivalent to 50 mg/day or higher, have a 
10% fracture rate per year, with a twofold higher risk than 
patients not using opioids [112]. Besides OPIAD, other fac-
tors may explain the relationship between opioid use and 
osteoporotic fractures. Opioids have a direct effect on bone 
formation by impairing osteoblastic activity via MOP recep-
tors [86, 111]. In animal models, tramadol, which has lower 
affinity for the MOP receptor than morphine or fentanyl, is 
also associated with a lower incidence of osteoporosis than 
these agents [13]. The incidence of fractures may also be 
affected by the CNS effects of opioids, such as dizziness and 
sedation, which can play an important role in opioid-related 
falls [86].
Body composition and  cardiovascular risk Several epide-
miological studies have documented an association between 
CNCP, opioid use and obesity [113, 114]. The reasons of 
this association are multifactorial. Physical limitations and 
depression related to CNCP may reduce energy expenditure 
and increase food intake [113, 114]. Conversely, opioids 
can modulate eating behavior [115]; as such, the combina-
tion therapy of naltrexone and bupropion has been approved 
for the treatment of obesity [115]. In addition, OPIAD can 
contribute to opioid-induced obesity. Observational stud-
ies have documented a close association between hypog-
onadism in adulthood and obesity or metabolic diseases [78, 
92], partially restored by TTh [76, 116–118].
A possible relationship between low testosterone and 
increased cardiovascular risk has also been suggested 
[119–121]. However, it is not clear whether low testosterone 
in aging men plays a direct pathogenic role in cardiovascu-
lar disease, is a marker of poor health, or even a protective 
mechanism, turning off testosterone-dependent functions 
(such as reproduction and/or physical and sexual activity) 
when cardiovascular function is impaired [122, 123]. A large 
UK general practice research database found an increased 
risk of myocardial infarction in 1.7 million patients with at 
least one prescription for an opioid to treat CNCP between 
1990 and 2008, especially in patients treated with morphine, 
meperidine and polytherapy [124]. The possible contribution 
of OPIAD was not investigated in this study.
Management of opioid‑induced androgen deficiency
OPIAD is a reversible condition, and opioid withdrawal may 
normalize testosterone levels within 1 month in subjects 
with heroin addiction [125]. Similar data are not available in 
men with CNCP, but discontinuing an opioid molecule with 
lower effect on the HPG axis may be an option for sympto-
matic men with reduced testosterone levels. If discontinu-
ing opioids is mandatory, non-opioid treatment should be 
considered for managing chronic pain in these patients. 
According to current guidelines, if pain relief with non-
opioids is inadequate or patients are unable to discontinue 
opioid treatment, TTh should be considered [126–128]. A 
limited number of studies have evaluated the effects of TTh 
in men with OPIAD (Table 3) [129–133]. In the only rand-
omized controlled trial available, TTh reduced mechanical 
hyperalgesia and improved sexual desire and overall quality 
of life [130]. The improvement of sexual function and pain 
relief after TTh was confirmed in other prospective and ret-
rospective observational trials [129, 131–133]. The effects 
of TTh observed in men with OPIAD are consistent with the 
effects observed in the general population [109, 119, 134]. 
There is no general agreement among different societies on 
the ideal minimum levels of total testosterone for initiat-
ing TTh; the International Society for Sexual Medicine and 
the Endocrine Society have defined a minimum testosterone 
level of 12 nmol/L and 9.4 nmol/L, respectively, [126, 128]. 
Meta-analyses have shown that TTh improves all aspects of 
sexual function when the total testosterone level is below 
12 nmol/L (3.5 ng/mL) [134, 135]. Similar beneficial effects 
of TTh have been observed for other outcomes, such as body 
composition (central adiposity, lean body mass) and glyco-
metabolic parameters [109, 119].
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The effects of available testosterone preparations have 
been previously reviewed [109, 136]. In summary, trans-
dermal gel preparations, as well as long-acting injectable 
testosterone undecanoate, should be preferred over older 
short-acting injectable or oral testosterone formulations due 
to their better efficacy and safety profiles [109, 136, 137]. 
Side-by-side comparisons of different testosterone products 
are lacking and the choice of testosterone preparation should 
be discussed with the patient and the final decision based on 
the clinical situation.
Conclusions
OPIAD is a common AE of opioid treatment in men with 
CNCP. The presence of OPIAD can negatively affect pain 
relief and impair sexual function, mood and overall quality 
of life. However, it is important to recognize that testos-
terone levels in men progressively decrease as a function 
of age and comorbidities, which are common in patients 
with CNCP. Therefore, physicians should consider measur-
ing testosterone levels in all men, before prescribing opioid 
treatment, and selecting opioids with a lower MOP affinity. 
In symptomatic patients with OPIAD, if opioid discontinu-
ation is unlikely, TTh may be initiated; however, this deci-
sion should be discussed with the patient, emphasizing that, 
although there is some evidence to support positive short-
term outcomes, the long-term effect of TTh in men with 
OPIAD is unknown.
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